Edition:
United States

Essex Bio-Technology Ltd (1061.HK)

1061.HK on Hong Kong Stock

5.13HKD
22 Sep 2017
Change (% chg)

HK$-0.07 (-1.35%)
Prev Close
HK$5.20
Open
HK$5.10
Day's High
HK$5.15
Day's Low
HK$5.01
Volume
646,000
Avg. Vol
273,158
52-wk High
HK$5.48
52-wk Low
HK$3.17

Chart for

About

Essex Bio-Technology Limited is an investment holding company principally engaged in the manufacture and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Company develops biopharmaceutical drugs based on recombinant deoxyribonucleic acid (DNA) technology. The main brands of... (more)

Overall

Beta: 0.84
Market Cap(Mil.): HK$2,883.82
Shares Outstanding(Mil.): 562.15
Dividend: 0.03
Yield (%): 0.80

Financials

  Industry Sector
P/E (TTM): -- 31.66 16.34
EPS (TTM): -- -- --
ROI: -- 15.09 14.66
ROE: -- 16.32 14.00

BRIEF-Essex Bio-Technology posts HY profit attributable of HK$77.1 mln

* HY profit attributable HK$77.1 million versus HK$62 million

Aug 11 2017

BRIEF-Essex Bio-Technology announces approval to commercialise Tobramycin eye drops in China

* Announces approval to commercialise preservative-free single-dose Tobramycin eye drops in China

Jun 13 2017

BRIEF-Essex Bio-Technology enters research project deal with AC Immune

* Deal to collaborate in pre-clinical and clinical co-development of novel biological therapeutic to treat neurodegenerative diseases Source text for Eikon: Further company coverage:

May 21 2017

Earnings vs. Estimates